Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$24.6 million.

  • Capricor Therapeutics' Net Income towards Common Stockholders fell 9567.63% to -$24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$57.5 million, marking a year-over-year decrease of 6825.08%. This contributed to the annual value of -$40.4 million for FY2024, which is 8059.67% down from last year.
  • Capricor Therapeutics' Net Income towards Common Stockholders amounted to -$24.6 million in Q3 2025, which was down 9567.63% from -$25.9 million recorded in Q2 2025.
  • Capricor Therapeutics' 5-year Net Income towards Common Stockholders high stood at -$829093.0 for Q4 2023, and its period low was -$25.9 million during Q2 2025.
  • Its 5-year average for Net Income towards Common Stockholders is -$9.3 million, with a median of -$7.2 million in 2023.
  • In the last 5 years, Capricor Therapeutics' Net Income towards Common Stockholders soared by 8921.39% in 2023 and then tumbled by 74565.53% in 2024.
  • Quarter analysis of 5 years shows Capricor Therapeutics' Net Income towards Common Stockholders stood at -$6.4 million in 2021, then fell by 20.79% to -$7.7 million in 2022, then skyrocketed by 89.21% to -$829093.0 in 2023, then tumbled by 745.66% to -$7.0 million in 2024, then tumbled by 250.44% to -$24.6 million in 2025.
  • Its Net Income towards Common Stockholders was -$24.6 million in Q3 2025, compared to -$25.9 million in Q2 2025 and -$7.0 million in Q4 2024.